The ballooning obesity drug market may have a new contender after Roche struck a $5.3 billion deal to develop Danish ...

The pharmaceutical firm Novo Nordisk is pursuing a multi-pronged strategy to regain market share that it has lost to Eli ...

But Eli Lilly CEO David Ricks waved off the deal Thursday, telling Yahoo Finance in an interview that the company is focused ...

Novo Nordisk's collaboration with telehealth providers offers semaglutide at $499/month, enhancing access for self-paying ...

Starting on July 1, Wegovy will become the preferred GLP-1 for obesity treatment on CVS Caremark’s largest commercial ...

Wegovy to become preferred GLP-1 drug on CVS Caremark's top formularies in 2025 as Novo Nordisk expands patient access ...

CVS and Novo Nordisk have struck a deal that will see the drugstore chain offering the Wegovy weight-loss drug to customers ...

CVS said it will expand access to blockbuster weight loss drug Wegovy for patients covered by its pharmacy benefit manager, Caremark.

Eli Lilly’s stock wobbled Thursday after a looming coverage hit was detailed for its blockbuster weight-loss drug Zepbound.

The deal could expand access to its in-demand obesity drug at the expense of Eli Lilly, whose shares fell by double digits on ...

Aetna is once again retreating from the Affordable Care Act market, while its parent company notched a deal with Danish ...

Eli Lilly CEO David Ricks is confident that weight loss med Zepbound is gaining market share at the expense of Wegovy, even as its rival strikes deals with CVS and Hims & Hers pharmacies.